The Guardians' right-hander pitched another gem Thursday, only to be undone by defensive miscues and a bizarre ...

Cleveland's MVP candidate continues building his Hall of Fame case as he nears milestone that would put him ahead of ...

The sixth and final game between the Guardians and Blue Jays this season ended with more than just a 6-0 Toronto victory — it concluded with visible tension, unmasked intentions, and a candid look ...

As the Guardians’ offense continues to sputter along at just 3.7 runs per game, the clamor for reinforcements grows louder among the fanbase. Two intriguing options are emerging from within the ...

ARM Holding Company, one of Nigeria’s foremost investment management firms, ... ARM announces new CEO as part of strategic leadership transition. Published. on. June 25, 2025. By.

New study arm (Part D) is part of the broad clinical development plan of the ITM-91/ITM-94 theranostic program in patients with Carbonic Anhydrase IX (CAIX)-expressing tumors Part D builds on ...

Garching / Munich, Germany, and Lausanne, Switzerland - June 23, 2025 - ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and Debiopharm, a Swiss-based, global ...

ARM announces new CEO as part of strategic leadership transition The announcement follows the planned exit of Ms Jumoke Ogundare, the current Group CEO, who will step down on 30 June, 2025, after ...

He currently serves as Deputy CEO of ARM Holding Company and has previously held leadership roles across key subsidiaries, including ARM Pension Managers, ARM Securities, and ARM Properties Plc.

ARM announces new CEO as part of strategic leadership transition. by Press Release. June 25, 2025 10:50 am. ARM Holding Company, one of Nigeria’s foremost investment management firms, ...

The initiation of this study arm represents a significant advancement for ITM and Debiopharm following their licensing agreement. In the now initiated Part D of the trial, ITM-94 is being evaluated ...